Global Custom Market Research Reports Provider Company

phone

aTyr Pharma Inc (LIFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 47
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

aTyr Pharma Inc (aTyr Pharma) is a biotherapeutics company that discovers and develops physiocrine-based therapies. The companys resolaris is a potential intravenous protein therapeutic for the treatment of rare myopathies with an immune component. It offers phyisiocrine, which is a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in different physiologic settings. aTyr Pharma develops drugs for cancer, neurodegenerative diseases, inflammation, and metabolic disorders. The company collaborates with research institutions for its research and development activities. It has presence in the US and Hong Kong. aTyr Pharma is headquartered in San Diego, California, the US.

aTyr Pharma Inc (LIFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Partnerships 14
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
Equity Offering 16
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 16
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 17
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 19
aTyr Pharma Raises USD86.3 Million in IPO of Shares 20
aTyr Pharma Inc - Key Competitors 22
aTyr Pharma Inc - Key Employees 23
aTyr Pharma Inc - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Mar 19, 2018: aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update 25
Nov 14, 2017: aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update 27
Aug 14, 2017: aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline 29
May 11, 2017: aTyr Pharma Announces First Quarter 2017 Operating Results 31
Mar 16, 2017: aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results 33
Corporate Communications 35
Nov 01, 2017: aTyr Pharma Announces Leadership Transition 35
Apr 10, 2017: aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors 36
Apr 03, 2017: aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors 37
Product News 38
12/21/2017: aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium 38
09/27/2017: aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society 39
05/15/2017: aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar 40
04/24/2017: aTyr Pharma Announces Promising Top-Line Results from Resolaris Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy 41
04/24/2017: aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting 42
Product Approvals 43
Mar 03, 2017: aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 43
Feb 28, 2017: aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 44
Jan 18, 2017: FDA Grants Fast Track Designation for aTyrs Resolaris to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris 45
Clinical Trials 46
Nov 27, 2017: aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923) 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List Of Tables

List of Tables
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
aTyr Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 16
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 17
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 19
aTyr Pharma Raises USD86.3 Million in IPO of Shares 20
aTyr Pharma Inc, Key Competitors 22
aTyr Pharma Inc, Key Employees 23
aTyr Pharma Inc, Subsidiaries 24

List Of Figures

List of Figures
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Synopsis UCC/AP Atyrau Industrial Gas Production Plant Kazakhstan - Project Profile contains information on the scope of the project including project overview and location. The profile also details project

View Report

Synopsis MoTC Makat-Kandyagash Railway Line Electrification Atyrau - Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership

View Report

aTyr Pharma Inc (aTyr Pharma) is a biotherapeutics company that discovers and develops physiocrine-based therapies. The companys resolaris is a potential intravenous protein therapeutic for the treatment of rare myopathies

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports